


**ADE
& COMPANY**



PATENT AND TRADE MARK AGENTS

03 CO
Box 500

ADRIAN D. BATTISON, B.Sc., F.P.T.I.C.
MICHAEL R. WILLIAMS, B.Sc., Ph.D.
RYAN W. DUPUIS, B.Sc.

Technical Assistant
JAMES A. BATTISON

Consultants
RONALD S. ADE, L.L.B. TRADE MARK AGENT
STEVEN Z. RABER, L.L.B. TRADE MARK AGENT

1700 - 360 MAIN STREET
WINNIPEG, MANITOBA
CANADA R3C 3Z3

Telephone (204) 947-1429
Facsimile (204) 942-5723
E-Mail: info@adeco.com
Web page: www.adeco.com

OUR FILE: 84894-602

YOUR FILE:

April 2, 2002

Commissioner for Patents
USPTO
Washington, DC 20231

Dear Sir:

RE: NUCLEOTIDE SEQUENCE DISCLOSURE for USSN 09/878918
Inventor: Gordon W. Glazner

In response to the Notice to Comply with requirements for patent applications containing nucleotide sequences dated February 5, 2002, we enclose herewith a sequence listing as per the request.

In response to the notice of incomplete reply, we note that we discussed the situation with Mr. Bob Wax of the USPTO who indicated that even though the sequences appearing on page 47 lines 15 (SEQ ID No. 1, NF- κ B binding site) and 16 (SEQ ID No. 2, CREB binding site) are not novel and do not appear in the claims, they must still be included in a sequence listing.

I hereby declare that the printed copy of the sequence listing and the electronic copy of the sequence listing are identical and as are they appear in the specification as filed.

Yours truly,


ADE & COMPANY

Per:

DR. MICHAEL R. WILLIAMS
Email: williams@adeco.com
Direct Line: 957-8364
MRW/dj



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/878,918	06/13/2001	Gordon W. Glazner	84894-602

CONFIRMATION NO. 2276

23529
ADE & COMPANY
1700-360 MAIN STREET
WINNIPEG, MB R3C3Z3
CANADA

RECEIVED

FORMALITIES LETTER



OC000000007424327

FEB 19 2002

Date Mailed: 02/05/2002

ADE & COMPANY

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Mulupete Bafel

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY